Page 3 - Tyrosine Kinase Activity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Pharma AG: Novartis Scemblix, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week

United statesEast hanoverIsabella zinckJeff legosAmy wolfNicole zinsli sommFloriana riccio furnariSamir shahParag mahantiJulie masowJorgee cortesSloan simpsonAlina levchukAmerican society of clinical oncologyEuropean hematology associationNovartis oncology communications

Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEast hanoverJeff legosJulie masowJorgee cortesSloan simpsonAmy wolfPrnewswire novartisFloriana riccio furnariAmerican society of clinical oncologyEuropean hematology associationExchange commissionGlobal head of oncology hematology developmentApproval programAugusta universityNj novartis pharmaceuticals corporation

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

United statesEast hanoverNovartis scemblixIsabella zinckJeff legosThomas hungerbuehlerFloriana riccio furnariMichaelj mauroSamir shahParag mahantiJulie masowSloan simpsonAlina levchukNovartis oncology congress hubNovartis oncology communicationsNovartis us external communications

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

/PRNewswire/ Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in.

United statesEast hanoverMichaelj mauroJeff legosJulie masowSloan simpsonPrnewswire novartisFloriana riccio furnariNovartis oncology congress hubNovartis oncology communicationsNovartis us external communicationsExchange commissionApproval programNj novartis pharmaceuticals corporationAmerican society of hematology annual meeting expositionNovartis pharmaceuticals corp

Novartis Pharma AG: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif (bosutinib) and lower discontinuation rate due to adverse

United statesEast hanoverIsabella zinckJeff legosThomas hungerbuehlerFloriana riccio furnariMichaelj mauroSamir shahParag mahantiJulie masowSloan simpsonAlina levchukNovartis oncology congress hubNovartis oncology communicationsNovartis us external communicationsNovartis external communications